# Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers

> **NCT03864406** · PHASE1 · COMPLETED · sponsor: **National Institutes of Health Clinical Center (CC)** · enrollment: 12 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Cobicistat
- **DRUG:** Darunavir/Cobicistat
- **DRUG:** Rivaroxaban

## Key facts

- **NCT ID:** NCT03864406
- **Lead sponsor:** National Institutes of Health Clinical Center (CC)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-04
- **Primary completion:** 2022-12-10
- **Final completion:** 2022-12-10
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03864406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03864406, "Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT03864406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*